Biotech
Verve Therapeutics
Verve Therapeutics raises $213M Series C at $1B valuation
$213M
Total Raised
Series C
Latest Round
2018
Founded
200+
Employees
26 Landsdowne Street, Cambridge, MA 02139
1 min read
Quick Facts
Valuation
$1B
Latest Round Size
$213M
Latest Round Date
October 2024
Verve Therapeutics: Series C Funding Round
Verve Therapeutics has successfully raised $213M in Series C funding, reaching a valuation of $1B.
Company Overview
Gene editing for heart disease
Funding Details
The Series C round was led by Foresite Capital, with participation from GV, F-Prime Capital, ARCH Venture Partners, Biomatics Capital.
Company Information
- Headquarters: 26 Landsdowne Street, Cambridge, MA 02139
- Founded: 2018
- Employees: 200+
- Category: Biotech
Investment
Verve Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Foresite Capital: Verified investor in Series C
- GV: Verified investor in Series C
- F-Prime Capital: Verified investor in Series C
- ARCH Venture Partners: Verified investor in Series C
- Biomatics Capital: Verified investor in Series C
Key Investors
Foresite Capital
Lead Investor
Verified investor in Series C
GV
Investor
Verified investor in Series C
F-Prime Capital
Investor
Verified investor in Series C
ARCH Venture Partners
Investor
Verified investor in Series C
Biomatics Capital
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M